Data.source	Date.of.update	Alternative.name	Product.type	Antibacterial.class	Indications	Route.of.administration	R.D.phase	Clinical.trials	Developer	Pathogen.category	Pathogen.name	Pathogen.activity	Active.against.priority.pathogens.	Innovative.	NCE.	Mycobacterium.tuberculosis	Clostridioides.difficile	Combined.Categories
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Enterococcus faecium	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
WHO AMR pipeline analysis	01 Nov-21	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Afabicin
WHO AMR pipeline analysis	01 Nov-21	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
WHO AMR pipeline analysis	01 Nov-21	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Afabicin
WHO AMR pipeline analysis	01 Nov-21	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
WHO AMR pipeline analysis	01 Nov-21	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
WHO AMR pipeline analysis	01 Nov-21	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Afabicin
WHO AMR pipeline analysis	01 Nov-21	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
WHO AMR pipeline analysis	01 Nov-21	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Enterobacterales	Critical priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
WHO AMR pipeline analysis	01 Nov-21	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
WHO AMR pipeline analysis	01 Nov-21	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
WHO AMR pipeline analysis	01 Nov-21	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
WHO AMR pipeline analysis	01 Nov-21	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
WHO AMR pipeline analysis	01 Nov-21	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
WHO AMR pipeline analysis	01 Nov-21	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	ARX-1796
WHO AMR pipeline analysis	01 Nov-21	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
WHO AMR pipeline analysis	01 Nov-21	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
WHO AMR pipeline analysis	01 Nov-21	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
WHO AMR pipeline analysis	01 Nov-21	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
WHO AMR pipeline analysis	01 Nov-21	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
WHO AMR pipeline analysis	01 Nov-21	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	ARX-1796
WHO AMR pipeline analysis	01 Nov-21	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	ARX-1796
WHO AMR pipeline analysis	01 Nov-21	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
WHO AMR pipeline analysis	01 Nov-21	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	ARX-1796
WHO AMR pipeline analysis	01 Nov-21	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	ARX-1796
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Benapenem
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Benapenem
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Benapenem
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Benapenem
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Benapenem
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	Inconclusive	Yes	No	Unknown	BWC0977
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	Inconclusive	Yes	No	Unknown	BWC0977
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	BWC0977
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Inconclusive	Yes	No	Unknown	BWC0977
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	BWC0977
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	BWC0977
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	Inconclusive	Yes	No	Unknown	BWC0977
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Enterococcus faecium	Other priority pathogens	Yes	Inconclusive	Yes	No	Unknown	BWC0977
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	BWC0977
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	BWC0977
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	BWC0977
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	BWC0977
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	BWC0977
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	LCB01-0371	Antibiotics	Oxazolidinone	Pulmonary tuberculosis, Gram-positive bacterial infections	Oral	Phase II	NCT02836483, NCT04550832	LegoChem Biosciences Inc., HaiHe Biopharma	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	Yes	Unknown	Delpazolid
WHO AMR pipeline analysis	01 Nov-21	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
WHO AMR pipeline analysis	01 Nov-21	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
WHO AMR pipeline analysis	01 Nov-21	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Durlobactam + sulbactam
WHO AMR pipeline analysis	01 Nov-21	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
WHO AMR pipeline analysis	01 Nov-21	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
WHO AMR pipeline analysis	01 Nov-21	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
WHO AMR pipeline analysis	01 Nov-21	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
WHO AMR pipeline analysis	01 Nov-21	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
WHO AMR pipeline analysis	01 Nov-21	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Durlobactam + sulbactam
WHO AMR pipeline analysis	01 Nov-21	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Durlobactam + sulbactam
WHO AMR pipeline analysis	01 Nov-21	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
WHO AMR pipeline analysis	01 Nov-21	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
WHO AMR pipeline analysis	01 Nov-21	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	Durlobactam + sulbactam
WHO AMR pipeline analysis	01 Nov-21	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
WHO AMR pipeline analysis	01 Nov-21	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
WHO AMR pipeline analysis	01 Nov-21	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	EBL-1003
WHO AMR pipeline analysis	01 Nov-21	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
WHO AMR pipeline analysis	01 Nov-21	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
WHO AMR pipeline analysis	01 Nov-21	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
WHO AMR pipeline analysis	01 Nov-21	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
WHO AMR pipeline analysis	01 Nov-21	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
WHO AMR pipeline analysis	01 Nov-21	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	EBL-1003
WHO AMR pipeline analysis	01 Nov-21	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	EBL-1003
WHO AMR pipeline analysis	01 Nov-21	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
WHO AMR pipeline analysis	01 Nov-21	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	EBL-1003
WHO AMR pipeline analysis	01 Nov-21	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	EBL-1003
WHO AMR pipeline analysis	01 Nov-21	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Enmetazobactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Enmetazobactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Enmetazobactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Enmetazobactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	ETX0282 + cefpodoxime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	ETX0282 + cefpodoxime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	ETX0282 + cefpodoxime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	ETX0282 + cefpodoxime
WHO AMR pipeline analysis	01 Nov-21	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
WHO AMR pipeline analysis	01 Nov-21	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
WHO AMR pipeline analysis	01 Nov-21	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
WHO AMR pipeline analysis	01 Nov-21	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Enterobacterales	Critical priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
WHO AMR pipeline analysis	01 Nov-21	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
WHO AMR pipeline analysis	01 Nov-21	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
WHO AMR pipeline analysis	01 Nov-21	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
WHO AMR pipeline analysis	01 Nov-21	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
WHO AMR pipeline analysis	01 Nov-21	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
WHO AMR pipeline analysis	01 Nov-21	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Gepotidacin
WHO AMR pipeline analysis	01 Nov-21	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Gepotidacin
WHO AMR pipeline analysis	01 Nov-21	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Gepotidacin
WHO AMR pipeline analysis	01 Nov-21	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Gepotidacin
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	KBP-7072
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	KBP-7072
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	KBP-7072
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	KBP-7072
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	KBP-7072
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	KBP-7072
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	KBP-7072
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	KBP-7072
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	No	Unknown	KBP-7072
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	KBP-7072
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	KBP-7072
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	KBP-7072
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	KBP-7072
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Campylobacter spp.	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	MRX-8
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	MRX-8
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	MRX-8
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	MRX-8
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	MRX-8
WHO AMR pipeline analysis	01 Nov-21	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
WHO AMR pipeline analysis	01 Nov-21	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
WHO AMR pipeline analysis	01 Nov-21	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Nacubactam + meropenem
WHO AMR pipeline analysis	01 Nov-21	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
WHO AMR pipeline analysis	01 Nov-21	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
WHO AMR pipeline analysis	01 Nov-21	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
WHO AMR pipeline analysis	01 Nov-21	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
WHO AMR pipeline analysis	01 Nov-21	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
WHO AMR pipeline analysis	01 Nov-21	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Nacubactam + meropenem
WHO AMR pipeline analysis	01 Nov-21	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Nacubactam + meropenem
WHO AMR pipeline analysis	01 Nov-21	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
WHO AMR pipeline analysis	01 Nov-21	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
WHO AMR pipeline analysis	01 Nov-21	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Nacubactam + meropenem
WHO AMR pipeline analysis	01 Nov-21	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
WHO AMR pipeline analysis	01 Nov-21	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
WHO AMR pipeline analysis	01 Nov-21	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
WHO AMR pipeline analysis	01 Nov-21	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
WHO AMR pipeline analysis	01 Nov-21	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
WHO AMR pipeline analysis	01 Nov-21	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
WHO AMR pipeline analysis	01 Nov-21	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
WHO AMR pipeline analysis	01 Nov-21	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
WHO AMR pipeline analysis	01 Nov-21	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
WHO AMR pipeline analysis	01 Nov-21	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Nafithromycin
WHO AMR pipeline analysis	01 Nov-21	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Nafithromycin
WHO AMR pipeline analysis	01 Nov-21	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Nafithromycin
WHO AMR pipeline analysis	01 Nov-21	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	No	Unknown	Nafithromycin
WHO AMR pipeline analysis	01 Nov-21	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Other priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Other priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX9003
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Other priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX9003
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX9003
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX9003
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX9003
WHO AMR pipeline analysis	01 Nov-21	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
WHO AMR pipeline analysis	01 Nov-21	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
WHO AMR pipeline analysis	01 Nov-21	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
WHO AMR pipeline analysis	01 Nov-21	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Other priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
WHO AMR pipeline analysis	01 Nov-21	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
WHO AMR pipeline analysis	01 Nov-21	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
WHO AMR pipeline analysis	01 Nov-21	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
WHO AMR pipeline analysis	01 Nov-21	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
WHO AMR pipeline analysis	01 Nov-21	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Enterobacterales	Critical priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
WHO AMR pipeline analysis	01 Nov-21	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	RG6006
WHO AMR pipeline analysis	01 Nov-21	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
WHO AMR pipeline analysis	01 Nov-21	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
WHO AMR pipeline analysis	01 Nov-21	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	RG6006
WHO AMR pipeline analysis	01 Nov-21	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
WHO AMR pipeline analysis	01 Nov-21	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	No	Unknown	Solithromycin
WHO AMR pipeline analysis	01 Nov-21	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Solithromycin
WHO AMR pipeline analysis	01 Nov-21	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Solithromycin
WHO AMR pipeline analysis	01 Nov-21	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Solithromycin
WHO AMR pipeline analysis	01 Nov-21	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Solithromycin
WHO AMR pipeline analysis	01 Nov-21	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Solithromycin
WHO AMR pipeline analysis	01 Nov-21	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Solithromycin
WHO AMR pipeline analysis	01 Nov-21	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Solithromycin
WHO AMR pipeline analysis	01 Nov-21	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Solithromycin
WHO AMR pipeline analysis	01 Nov-21	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Solithromycin
WHO AMR pipeline analysis	01 Nov-21	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Solithromycin
WHO AMR pipeline analysis	01 Nov-21	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Solithromycin
WHO AMR pipeline analysis	01 Nov-21	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Solithromycin
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	SPR-206
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	SPR-206
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	SPR-206
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	SPR-206
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	SPR-206
WHO AMR pipeline analysis	01 Nov-21	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
WHO AMR pipeline analysis	01 Nov-21	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
WHO AMR pipeline analysis	01 Nov-21	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
WHO AMR pipeline analysis	01 Nov-21	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
WHO AMR pipeline analysis	01 Nov-21	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
WHO AMR pipeline analysis	01 Nov-21	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
WHO AMR pipeline analysis	01 Nov-21	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
WHO AMR pipeline analysis	01 Nov-21	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
WHO AMR pipeline analysis	01 Nov-21	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
WHO AMR pipeline analysis	01 Nov-21	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
WHO AMR pipeline analysis	01 Nov-21	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
WHO AMR pipeline analysis	01 Nov-21	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
WHO AMR pipeline analysis	01 Nov-21	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Helicobacter pylori	Other priority pathogens	Yes	No	Yes	No	Unknown	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	Yes	Yes	No	Unknown	Taniborbactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Other priority pathogens	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	Yes	Yes	No	Unknown	Taniborbactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Yes	Yes	No	Unknown	Taniborbactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Yes	Yes	No	Unknown	Taniborbactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2092
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Possibly	No	Yes	No	Unknown	TNP-2092
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2092
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	Possibly	No	Yes	No	Unknown	TNP-2092
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2092
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	Possibly	No	Yes	No	Unknown	TNP-2092
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Possibly	No	Yes	No	Unknown	TNP-2092
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	Possibly	No	Yes	No	Unknown	TNP-2092
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2092
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2092
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2092
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2092
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2092
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2198
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2198
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2198
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	TNP-2198
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Possibly	No	Yes	No	Unknown	TNP-2198
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	Yes	No	Yes	No	Unknown	TNP-2198
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2198
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2198
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2198
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2198
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2198
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2198
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2198
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Helicobacter pylori	Other priority pathogens	Possibly	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Enterococcus faecium	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Campylobacter spp.	Other priority pathogens	Possibly	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	No	Unknown	TXA709
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	Yes	Yes	No	Unknown	TXA709
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Yes	Yes	No	Unknown	TXA709
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	TXA709
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Yes	Yes	No	Unknown	TXA709
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	No	Unknown	TXA709
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	TXA709
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	No	Unknown	TXA709
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	Yes	Yes	No	Unknown	TXA709
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Yes	Yes	No	Unknown	TXA709
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	No	Unknown	TXA709
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	TXA709
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Yes	Yes	No	Unknown	TXA709
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Other priority pathogens	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Possibly	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Possibly	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Zidebactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Zidebactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Zidebactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Zidebactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	Zidebactam + cefepime
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Zoliflodacin
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Zoliflodacin
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Enterobacterales	Critical priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
WHO AMR pipeline analysis	01 Nov-21	GSK070	Antibiotics	Leu RS inhibitor (oxaborole)	Pulmonary tuberculosis	Oral	Phase II	NCT03557281	GlaxoSmithKline PLC	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	 GSK3036656
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	DprE1 inhibitor (benzothiazinone)	Tuberculosis	Oral	Phase II	NCT03590600, NCT04044001	University of Munich; Hans Knöll Institute, Jena; German Center for Infection Research	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	BTZ-043
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Amido piperidine (inactivation of TetR-like repressor, EthR2)	Tuberculosis	Oral	Phase I	NCT04654143	Bioversys/ GSK	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	Miscellaneous
WHO AMR pipeline analysis	01 Nov-21	LCB01-0371	Antibiotics	Oxazolidinone	Pulmonary tuberculosis, Gram-positive bacterial infections	Oral	Phase II	NCT02836483, NCT04550832	LegoChem Biosciences Inc., HaiHe Biopharma	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	Delpazolid
WHO AMR pipeline analysis	01 Nov-21	GSK286	Antibiotics	Undisclosed	Tuberculosis	Oral	Phase I	NCT04472897	GSK. TB Drug Accelarator/ Bill & Melinda Gates Foundation	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	GSK2556286
WHO AMR pipeline analysis	01 Nov-21	PBTZ-169	Antibiotics	DprE1 inhibitor (Benzothiazinone)	Pulmonary tuberculosis	Oral	Phase I	NCT03036163, NCT03776500, NCT03334734	Innovative Medicines for Tuberculosis Foundation and Nearmedic Plus	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	Macozinone
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DprE1 inhibitor (3,4-dihydrocarbostyril)	Pulmonary tuberculosis	Oral	Phase II	NCT03678688	Otsuka Pharmaceutical Co., Ltd.	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	OPC-167832
WHO AMR pipeline analysis	01 Nov-21	PNU-100480	Antibiotics	Oxazolidinone	Pulmonary tuberculosis, Gram-positive bacterial infections	Oral	Phase II	NCT03959566	TB Alliance/ Sequella	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	Sutezolid
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DprE1 inhibitor (azaindole)	Tuberculosis	Oral	Phase II	NCT04176250, NCT03199339	TB Alliance/ Bill & Melinda Gates Medical Research Institute/ Foundation for Neglected Disease Research	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	TBA-7371
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diarylquinoline	Tuberculosis	Oral	Phase I	NCT04890535	TB Alliance	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	TBAJ-587
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Diarylquinoline	Tuberculosis	Oral	Phase I	NCT04493671	TB Alliance	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	TBAJ-876
WHO AMR pipeline analysis	01 Nov-21	pyrifazimine	Antibiotics	Riminophenazine (clofazimine-analogue)	Tuberculosis	Oral	Phase I	NCT04670120	Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	TBI-166
WHO AMR pipeline analysis	01 Nov-21	None	Antibiotics	Oxazolidinone	Tuberculosis	Oral	Phase I	NCT03758612, NCT04865536	Institute of Materia Medica/ TB Alliance	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	TBI-223
WHO AMR pipeline analysis	01 Nov-21	Q203	Antibiotics	Imidazopyridine amide	Pulmonary tuberculosis	Oral	Phase II	NCT03563599, NCT04847583	Qurient Co	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	Telacebec
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	C. difficile infections	Oral	Phase I	NCT04891965	Artugen Therapeutics	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	Recurring C. difficile infections	Colonoscopy	Preregistration	None	BiomeBank	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	Live biotherapeutic product	Recurring C. difficile infections	Oral	Phase II	NCT03110133, NCT03497806	Finch Theraputics	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	REP 3123	Antibiotics	 Diaryldiamine (Methionyl-tRNA synthetase inhibitor)	C. difficile infections	Oral	Phase II	NCT04781387	Crestone/ National Institute of Allergy and Infectious Diseases	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	Yes	Yes	No	Yes	CRS3123
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	Antibiotic inactivator and protective colon-targeted adsorbent	C. difficile infections	Oral	Phase II	NCT03710694	Da Volterra	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	MCB-3837	Antibiotics	Oxazolidinone-quinolone hybrid	C. difficile infections	IV	Phase II	NCT03988855	Deinove	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	Inconclusive	Yes	No	Yes	DNV3837
WHO AMR pipeline analysis	01 Nov-21	ACX-362E	Antibiotics	Substituted guanine (DNA polymerae IIIIC inhibitor))	C. difficile infections	Oral, Not absorbed	Phase II	NCT04247542	Acurx Pharmaceuticals	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	Yes	Yes	No	Yes	Ibezapolstat
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	anti-C. difficile polcyclonal Ab	C. difficile infections	Oral	Phase II	NCT04121169	ImmuniMed	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Antibodies
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Phage endolysin and three toxin-binding proteins (5D, E3, and 7F)s	C. difficile infections	Oral	Phase I	NCT04893239	Lumen Bioscience	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Bacteriophages and phage-derived enzymes
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	Recurring C. difficile infections	Oral	Phase I	NCT02865616, NCT04602715	NuBiyota/ Takeda	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	–	Antibiotics	DNA minor groove binder (distamycin)	C. difficile-associated diarrhea	Oral, Not absorbed	Phase II	NCT03824795	MGB Biopharma Ltd.	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	Yes	Yes	No	Yes	MGB-BP-3
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	C. difficile	Enema	Phase III	NCT03931941	Ferring Pharmaceuticals	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	Recurring C. difficile infections	Oral	Phase I	NCT02981316	Ferring (Rebiotix)	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	SMT19969	Antibiotics	Bis-benzimidazole	C. difficile infections	Oral, Not absorbed	Phase III	NCT02784002, NCT02092935, NCT03595553, NCT03595566, NCT04802837	Summit Therapeutics Inc.	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	Yes	Yes	No	Yes	Ridinilazole
WHO AMR pipeline analysis	01 Nov-21	None	Non-traditional	Live biotherapeutic product	C. difficile infections	Oral	Phase III	NCT03183128, NCT03183141	Seres Theraputics	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	Ribaxamase	Non-traditional	Antibiotic inactivator	C. difficile infections	Oral	Phase II	NCT02563106, NCT04692181	Synthetic Biologics	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
WHO AMR pipeline analysis	01 Nov-21	–	Non-traditional	Live biotherapeutic product	Recurring C. difficile infections	Oral	Phase II	NCT03788434	Vedanta Biosciences	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
